IRIS
GROSSI, Laurino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.216
EU - Europa 5.323
AS - Asia 5.115
SA - Sud America 552
Continente sconosciuto - Info sul continente non disponibili 317
AF - Africa 55
OC - Oceania 6
Totale 19.584
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.076
SG - Singapore 1.956
CN - Cina 1.475
IT - Italia 893
UA - Ucraina 822
IE - Irlanda 730
TR - Turchia 582
RU - Federazione Russa 579
SE - Svezia 565
GB - Regno Unito 543
FR - Francia 431
BR - Brasile 428
VN - Vietnam 406
IN - India 380
DE - Germania 320
FI - Finlandia 180
BD - Bangladesh 78
AT - Austria 65
CA - Canada 65
PL - Polonia 57
HK - Hong Kong 48
AR - Argentina 40
MX - Messico 40
IQ - Iraq 33
EC - Ecuador 30
NL - Olanda 30
JP - Giappone 21
KR - Corea 21
EU - Europa 20
ID - Indonesia 19
BE - Belgio 18
ZA - Sudafrica 17
CO - Colombia 16
ES - Italia 16
RO - Romania 16
MA - Marocco 12
LT - Lituania 11
PK - Pakistan 11
IL - Israele 10
CL - Cile 9
PE - Perù 9
JO - Giordania 8
KE - Kenya 8
PY - Paraguay 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
JM - Giamaica 7
SA - Arabia Saudita 7
CH - Svizzera 6
GR - Grecia 6
AU - Australia 5
PH - Filippine 5
PS - Palestinian Territory 5
TW - Taiwan 5
VE - Venezuela 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
DZ - Algeria 4
EG - Egitto 4
IR - Iran 4
MY - Malesia 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BB - Barbados 3
EE - Estonia 3
ET - Etiopia 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
NI - Nicaragua 3
NO - Norvegia 3
OM - Oman 3
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GT - Guatemala 2
LB - Libano 2
LU - Lussemburgo 2
PA - Panama 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AP - ???statistics.table.value.countryCode.AP??? 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CU - Cuba 1
GD - Grenada 1
KH - Cambogia 1
LV - Lettonia 1
MD - Moldavia 1
MQ - Martinica 1
MU - Mauritius 1
Totale 19.278
Salva come PNG Salva come JPEG
Città #
Singapore 1.314
Jacksonville 945
San Jose 819
Chandler 779
Dublin 721
Dearborn 468
Council Bluffs 426
Ashburn 411
Southend 378
Princeton 354
Beijing 342
Dallas 314
Nanjing 284
Izmir 272
Wilmington 254
Los Angeles 216
Cambridge 157
Ho Chi Minh City 130
Santa Clara 127
Buffalo 122
Woodbridge 119
Ann Arbor 115
New York 111
Tongling 104
Nanchang 93
The Dalles 93
Hanoi 92
Houston 68
Boardman 66
Rome 64
Moscow 57
Hefei 56
Hebei 53
Vienna 52
Shenyang 48
Altamura 47
Munich 47
São Paulo 47
Redondo Beach 46
Kunming 45
Tianjin 43
Jiaxing 40
Hong Kong 37
Kraków 35
Pescara 35
Phoenix 35
Chieti 29
Hangzhou 29
Brooklyn 28
Bologna 27
Milan 25
Norwalk 25
Columbus 24
Da Nang 24
Dong Ket 22
Haiphong 22
Düsseldorf 20
Jinan 20
Changsha 19
Chicago 19
Tokyo 19
Washington 19
Ancona 18
Frankfurt am Main 18
Orange 18
Warsaw 18
Brussels 17
Seoul 17
Baghdad 16
Belo Horizonte 16
Guangzhou 16
Helsinki 16
Montreal 16
Atlanta 15
Bellante 15
Boston 15
Denver 15
Guayaquil 15
Turku 15
Amsterdam 14
Grevenbroich 14
Lanzhou 14
Orem 14
Vinh 14
Ankara 13
London 13
Nuremberg 13
Seattle 13
Charlotte 12
Mumbai 12
San Francisco 12
Toronto 12
Fuzhou 11
Stockholm 11
Falls Church 10
Guadalajara 10
Johannesburg 10
Poplar 10
Rio de Janeiro 10
Brasília 9
Totale 11.379
Salva come PNG Salva come JPEG
Nome #
Il tempo di transito oro-cecale (TTOC) è accelerato dopo somministrazione orale di allergene alimentare nei pazienti con sindrome del colon irritabile (SCI) e prick test positivo 408
EFFICACY OF TREATMENT WITH PYLERA IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER 398
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study 190
48-Hour continuous pH measurement in patients with gastro-oesophageal reflux: effect of cisapride. 177
Ottimizzazione di vedolizumab in RCU con perdita di risposta a infliximab 177
Beneficial effects of SR140333, a novel substance P antagonist, in a rat model of experimental colitis 176
Blood cardioplegia: could it protect the ischemic-reperfused human myocardium through antioxidant-type mechanisms? 173
SYMPTOM PATTERN IN FUNCTIONAL DYSPEPSIA AND GASTROESOPHAGEAL REFLUX DISEASE: ROLE OF H. PYLORI INFECTION 172
Alterazioni non litiasiche del contenuto colecistico 167
24-hour pancolonic motility using a portable electronic probe in healthy subjects 166
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy 164
SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis 161
Detection of Helicobacter pylori in the gastrointestinal tract of Balb/C euthymic mice infected by human Helicobacter pylori and evidence for transmission 157
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.Am. J. Gastroenterol 153
Anal canal diameters and pessure measured simultaneously by real time ultrasonography and manometry in human subjects 151
Two weeks regimen with amoxillicin, tinidazole and omeprazole eradicates helicobacter pylori and cures active duodenal ulcer 151
Alterazioni contrattili della muscolatura liscia nel corso di colite sperimentale sono ridotte da un antagonista specifico della sostanza P 148
Correlation between anal canal size and anal canal pressure: an ultrasonografhip and manometric study 144
FUSOBACTERIUM NUCLEATUM (FN) IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE 143
Trasmissione di Helicobacter pylori in un modello murino 142
COMBINED VIDEOCAPSULE ENDOSCOPY (VCE) AND LACTULOSE HYDROGEN BREATH TEST (LHBT): A COMPARATIVE STUDY TO ASSESS ORO-CECAL TRANSIT TIME (OCTT). 142
Diameters and pressures of the anal canal simultaneously measured with endosonography and manometry 138
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD) 138
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC) 138
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD). 138
Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. 136
Gastric antral and fundus receptive relaxation in dyspeptic patients and normal subjects 135
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 135
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC). 135
PRUCALOPRIDE ACCELERATES GASTRIC AND SMALL BOWEL TRANSIT TIMES OF VIDEOCAPSULES ENDOSCOPY 135
Morphological and motor changes during experimental colits in rats are prevented by a specific substance p antagonist 134
ESOPHAGITIS AND ITS CAUSES: WHO IS "GUILTY" WHEN ACID IS FOUND "NOT GUILTY"? 133
H2-RECEPTOR ANTAGONISTS ARE SCAVENGERS OF OXYGEN RADICALS 131
Distribuzione transmurale dei sistemi antiossidanti e della perossidazione lipidica nel ventricolo sinistro di coniglio 131
Prolonged anal sphincter manometry in normal human subjects 130
ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT 130
Pharyngeal, Esophageal and Gastric Motility in Normal Subjects and in patients with gastroesophageal Reflux Disease 129
A “REAL LIVE” EXPERIENCE OF INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 129
Short- and long-term omeplazole for the tratment and prevention of duodenal ulcer, and effect on helicobacter pylori 128
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 128
MIGRATING MOTOR COMPLEX RECORDED SPONTANEOUSLY AND INDUCED BY MOTILIN AND ERYTHROMYCIN IN AN EX VIVO RABBIT INTESTINAL PREPARATION 128
5-HT1-RECEPTOR AGONIST SUMATRIPTAN MODIFIES GASTRIC SIZE AFTER 500 ML OF WATER IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS 128
Treatment of Helicobacter pylori (Hp) infection with an association of Omeprazole and Roxytromicine: a study in vivo and in vitro. 126
Detection of Helicobacter pylori in esophagus and saliva in humans 125
USO DI GOLIMUMAB COME SECONDA LINEA BIOLOGICA IN UN PAZIENTE CON RETTOCOLITE ULCEROSA 125
Swallows, oesophageal and gastric motility in normal subjects and in patients with gastro-oesophageal reflux disease: a 24-h-pH-manometric study 124
Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. 124
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). 123
Erythromycin accellerates gastric and gallbladder emptying through a cholinergic mediated mechanism in humans 122
Oesophageal and gastric motility in patients with gastro-oesophageal reflux disease 121
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 121
CAN HELICOBACTER PYLORI INFECTION HAVE A ROLE ON CLINICAL APPEARANCE OF GERD? 121
EVALUATION OF LIVER BLOOD FLOW AND FIBROSIS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CIRRHOSIS IN COMPARISON WITH NORMAL CONTROLS THROUGH CONTRAST ENHANCED ULTRASOUND(CEUS) AND FIBROSCAN 120
Evidence for an oro-fecal transmission inan experimental murine model of helicobacter pylori infection. 119
Transmission of Helicobacter pylori in an animal model. 119
TYPICAL AND ATYPICAL SYMPTOMS OF GASTRO ESOPHAGEAL REFLUX DISEASE: DOES Helicobacter pylori MATTER? 119
PRUCALOPRIDE INCREASES BASAL LES TONE IN PATIENTS WITH ESOPHAGEAL MOTILITY DISORDERS 118
Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients 118
Peppermint oil (Mintoil®) in the treatment or irritable bowel syndrome: a prospective double blind placebo controlled randomized trial. 117
EFFECT OF CIMETROPIUM BROMIDE ON GALLBLADDER CONTRACTION IN RESPONSE TO ORAL AND INTRADUODENAL OLIVE OIL 117
EFFICACY AND SAFETY OF LONG-TERM INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 116
CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB ONE-HOUR INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY 116
Esophageal and gastric motility in patients with gastroesophageal reflux disease 114
Role of transient lower esophageal sphincter relaxations in the genesis of priximal gastro-esophageal reflux 114
Effect of glyceryl trinitrate ointment (GTO) 0.2% and 2% on anal canal pressure during acute and chronic application in patients with anal fissure 114
ESOPHAGEAL MOTILITY ASSESSMENT AFTER PRUCALOPRIDE ADMINISTRATION IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY (IEM) AND SYSTEMIC SCLEROSIS. 114
Distensione gastrica nei soggetti normali e nei pazienti dispeptici helicobacter pylori positivi e negativi e correlazione con i sintomi 113
LA MALDIGESTIONE 113
Registrazione delle 24 ore della motilità del piloro in soggetti normali 112
TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND GASTRO-ESOPHAGEAL REFLUX EPISODES IN HEALTHY SUBJECTS AND GERD PATIENTS DURING 24 HOURS 112
I RILASCIAMENTI TRANSITORI DELLO SFINTERE ESOFAGEO INFERIORE NELLA GENESI DEI REFLUSSI GASTRO-ESOFAGEI: PROSPETTIVE TERAPEUTICHE 111
SHORT AND LONG TERM EFFICACY OF GLYCERYL TRINITRATE (GTN) OINTMENT 0.2% AND 2% ON ANAL CANAL PRESSURE IN PATIENTS WITH CHRONIC ANAL FISSURES. 111
Increase of swallows before the onset of phase III of migrating motor complex in normal human subjects 111
DISORDINI MOTORI ASPECIFICI DELL’ESOFAGO 110
EFFECT OF THE 5-HT3 RECEPTOR ANTAGONIST, ONDANSETRON, ON GASTRIC SIZE IN DYSPEPTIC PATIENTS WITH IMPAIRED GASTRIC ACCOMODATION 110
ULTRASOUND(US) GRADED HEPATOSTEATOSIS ASSESSMENT THROUGH CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSCAN IN NON ALCOHOLIC FATTY LIVER DISEASE 110
EFFICACIA E SICUREZZA DEL RITRATTAMENTO CON INFLIXIMAB IN UN PAZIENTE AFFETTO DA MORBO DI CROHN 109
RISPOSTA CLINICA E GUARIGIONE DELLA MUCOSA DOPO 4 ANNI DI TERAPIA CON INFLIXIMAB IN UN PAZIENTE CON MALATTIA DI CROHN ILEALE STEROIDO-RESISTENTE 109
CLINICAL AND ECONOMIC EFFECT OF SHORT INFLIXIMAB INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTRE STUDY 109
EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON OESOPHAGEAL MOTOR PATTERN IN GORD PATIENTS WITH INEFFECTIVE OESOPHAGAL MOTILITY 108
FPSE-HPLC-PDA METHOD FOR THE DETERMINATION OF INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE 108
Proximal and Distal Gastric Distension in Normal Subjects and H. pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 107
EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: EVALUATION USING HIGH RESOLUTION MANOMETRY 107
THERAPY- RELATED ADVERS EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 107
SPONTANEOUS OPENING OF LES IN ACHALASIA: AN UNCOMMON ON-LINE DOCUMENTATION BY HIGH-RESOLUTION MANOMETRY 107
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMAMTORY BOWEL DISEASE (IG-IBD). 107
EFFECT OF THE 5-HT1 AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY 106
THERAPY-RELATED ADVERSE EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 106
Effect of nitric oxide on propagated clusters of spontaneous motor waves in an ex vivo rabbit intestinal preparation 106
Gastric antral and fundic distention evaluated by ultrasonography (US) in normal subjects and patients with idiopathic dyspepsia 105
Proximal and Distal Gastric Distension in Normal Subjects and H.pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 105
Relationship between interdigestive esophageal and gastric motility in humans 105
ROLE OF PRUCALOPRIDE (RESOLOR) IN THE SETTING-UP OF PILLCAM COLON-CAPSULE ENDOSCOPY (CCE). EXPERIENCEFROM A SINGLE CENTRE 105
EVALUATION OF INTRA PARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPARISON WITH NORMAL CONTROLS 105
Role of nitric oxide on peristaltic motor activity in an in vitro rabbit intestinal preparation 104
GRAVIDANZA IN UNA PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA IN TERAPIA CON INFLIXIMAB: CASO CLINICO 103
ON THE SPECIFICITY OF ALTERED MUSCLE FUNCTION IN EXPERIMENTAL COLITIS IN RATS 103
EFFECT OF HYOSCINE N-BUTYLBROMIDE ON GASTROESOPHAGEAL REFLUX IN NORMAL SUBJECTS AND PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. 103
Relationship between interdigestive esophageal and gastric motility in humans 103
GOLIMUMAB IN ULCERATIVE COLITIS. REAL-LIFE PROSPECTIVE COHORT STUDY FROM A SINGLE REFERRAL CENTRE OF MIDDLE ITALY. 103
Totale 13.167
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.753
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.753
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022739 0 0 4 200 46 16 24 66 54 9 88 232
2022/20232.154 188 207 108 264 194 488 145 158 253 41 59 49
2023/20241.002 79 51 62 36 34 292 236 37 14 44 19 98
2024/20252.576 182 423 292 47 54 66 99 173 310 121 252 557
2025/20265.419 488 252 637 543 453 328 787 407 577 430 424 93
2026/2027596 214 289 93 0 0 0 0 0 0 0 0 0
Totale 19.584